Search results

Skip to results

Type

Status

Last updated

Showing 1 to 6 of 6 results for idelalisib for lymphoma

  1. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

    Technology appraisal guidance
    Published
    2 October 2019
    View recommendations

    Sections for TA604

  2. Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.

    Technology appraisal guidance
    Published
    7 June 2023
    View recommendations

    Sections for TA894

  3. Mosunetuzumab for treating relapsed or refractory follicular lymphoma (TA892)

    Evidence-based recommendations on mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma in adults.

    Technology appraisal guidance
    Published
    31 May 2023
    View recommendations

    Sections for TA892

  4. Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

    Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 September 2014

  5. Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328)

    This guidance has been updated and replaced by NICE technology appraisal guidance 604.

    Technology appraisal guidance
    Published
    17 December 2014

  6. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

    Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    9 December 2020
    View recommendations

    Sections for TA663